Premium
LONG‐ACTING THYROID STIMULATOR: A REVIEW
Author(s) -
Joasoo A.
Publication year - 1970
Publication title -
medical journal of australia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.904
H-Index - 131
eISSN - 1326-5377
pISSN - 0025-729X
DOI - 10.5694/j.1326-5377.1970.tb116941.x
Subject(s) - thyroid , bioassay , medicine , endocrinology , hormone , iodine , intraperitoneal injection , thyroid stimulating hormone , endogeny , pituitary gland , chemistry , biology , genetics , organic chemistry
While working on a bioassay for pituitary thyroid‐stimulating hormone (TSH), Adams and Purves (1956) found that the serum of some patients with Graves' disease showed a maximal stimulating activity which, occurring at 16 to 24 hr after intraperitoneal injection, was much later than the normal response to thyroid‐stimulating hormone, at 1 ½ to 3 hr. This stimulating substance was, therefore, later named the “long‐acting thyroid stimulator” (LATS). These findings were confirmed by McKenzie (1958), who used mice instead of guinea‐pigs, and gave the injections intravenously. The method which he used is basically the one still used for bioassay of LATS, although many workers have modified it. After the administration of radioactive iodine to label the thyroxine in the thyroid gland, the mice are treated with thyroxine to suppress endogenous TSH production. After injection of TSH or sera containing LATS, serial samples of blood are taken and the radioactivity is counted. The thyroid stimulators lead to release of labelled thyroxine from the thyroid gland, thus elevating the blood radioactivity.